Program
doravirine
Also written as “Doravirine”, “DOR/ISL” and “Doravirine, Tenofovir, Lamivudine”.
Its studies are mostly in Acquired Immunodeficiency Syndrome · HIV Infections · Renal Insufficiency, led by Merck.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 152 open or running | phase 3since Oct 23, 2014 | Nov 4, 2011 | Nov 12, 2028phase 2 · NCT04375800 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 4, 2011First study: phase 1 study in HIV-1 InfectionFirst studyNCT01466985 · 18 enrolled
- Jun 28, 2012Phase 2 study in HIV InfectionsNCT01632345 · 342 enrolled
- Mar 14, 2014Phase 1 study in HIV-1 InfectionNCT02089659 · 16 enrolled
- Oct 23, 2014Phase 3 study in HIV-1NCT02275780 · 769 enrolled
- Mar 18, 20152 phase 3 studiesNCT02397096, NCT02403674
- Sep 11, 2015Phase 1 study in Human Immunodeficiency Virus-1 (HIV-1)NCT02549040 · 16 enrolled
- Dec 23, 2015Phase 1 study in Renal InsufficiencyNCT02641067 · 16 enrolled
- Jan 8, 2016Phase 2 study in HIV-1NCT02652260 · 86 enrolled
- Mar 17, 2016Phase 1 study in Acquired Immunodeficiency SyndromeNCT02715700 · 14 enrolled
- Sep 1, 2017Phase 2 study in HIV-1 InfectionNCT03272347 · 123 enrolled · United States, Chile, France and more
- Jan 15, 2020Phase 3 study in HIV-1 InfectionNCT04233216 · 35 enrolled · United States, Australia, Canada and more
- May 4, 2020Phase 2 study in Acquired Immunodeficiency SyndromeNCT04375800 · 84 planned · United States, Colombia, Dominican Republic and more
- Jul 18, 2025Phase 1 study in HealthyNCT07086079 · 12 enrolled · United States
- Oct 2, 2026Phase 2 study in HIV InfectionsNCT07862569 · 45 planned
Ahead
- Nov 12, 2028Primary completion: phase 2 study in Acquired Immunodeficiency SyndromeNCT04375800
- Sep 24, 2029Primary completion: phase 2 study in HIV InfectionsNCT07862569
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator”ChEMBL 37, by rule
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07862569HIV Infections | 2 | Not yet recruiting | Sep 24, 2029 | 45 |
| NCT07086079Healthy · United States | 1 | Completed | Dec 8, 2025 | 12 |
| NCT04375800Acquired Immunodeficiency Syndrome · United States, Colombia, Dominican Republic and more | 2 | Recruiting | Nov 12, 2028 | 84 |
| NCT04233216HIV-1 Infection · United States, Australia, Canada and more | 3 | Completed | Nov 21, 2022 | 35 |
| NCT03272347HIV-1 Infection · United States, Chile, France and more | 2 | Completed | Mar 8, 2021 | 123 |
| NCT02715700Acquired Immunodeficiency Syndrome | 1 | Completed | Jun 13, 2016 | 14 |
| NCT02652260HIV-1 | 2 | Completed | Aug 14, 2018 | 86 |
| NCT02641067Renal Insufficiency | 1 | Completed | May 14, 2016 | 16 |
| NCT02549040Human Immunodeficiency Virus-1 (HIV-1) | 1 | Completed | Dec 24, 2015 | 16 |
| NCT02403674Acquired Immunodeficiency Syndrome | 3 | Completed | Mar 20, 2017 | 734 |
| NCT02397096HIV-1 Infection | 3 | Completed | Feb 22, 2018 | 673 |
| NCT02275780HIV-1 | 3 | Completed | Sep 29, 2016 | 769 |
| NCT02089659HIV-1 Infection | 1 | Completed | May 12, 2014 | 16 |
| NCT01632345HIV Infections | 2 | Completed | Dec 3, 2014 | 342 |
| NCT01466985HIV-1 Infection | 1 | Completed | Apr 10, 2012 | 18 |
How it is read
Names in the registry
- “Doravirine”, 8 entries
- “DOR/ISL”, 2 entries
- “Doravirine, Tenofovir, Lamivudine”, 2 entries
- “Doravirine, Tenofovir, Lamivudine - Blinded”, 1 entry
- “DOR”, 1 entry
Codes read as this program: MK1439.
Conditions, from the studies’ own filings
- Acquired Immunodeficiency Syndrome, 3 studies
- HIV Infections, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.